Immuneering Corporation announced the appointment of Diana F. Hausman, M.D., Chief Medical Officer of Lengo Therapeutics (a wholly-owned subsidiary of Blueprint Medicines Corporation), to its Board of Directors. This appointment brings Immuneering's Board to six members. Diana has dedicated her career to creating new and better possibilities for cancer patients, as a Board certified oncologist with more than 20 years of clinical drug development experience at both privately held and publicly traded companies.

Dr. Hausman's broad pharmaceutical industry experience includes work with biologics, antibody-drug conjugates and targeted small molecules in the fields of oncology (including immunotherapy), hemostasis, hepatitis C, and Crohn's disease. Additionally, she is well versed in all aspects of drug development, including development and implementation of clinical strategy. Since June 2021, Dr. Hausman has been the Chief Medical Officer of Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology and now a wholly-owned subsidiary of Blueprint Medicines Corporation.

From 2016 to 2021, Dr. Hausman was Chief Medical Officer at Zymeworks Inc., responsible for the development and implementation of global clinical strategy for the company's preclinical and clinical stage products.